Karyopharm Therapeutics (NASDAQ: KPTI) Exceeds Q1 2026 Earnings and Revenue Estimates

Font: Financial Modeling Prep  • May 14, 2026

• Karyopharm Therapeutics (NASDAQ: KPTI) surpassed Q1 2026 EPS and revenue estimates, showcasing strong financial performance.
• Despite positive quarterly results, the company's negative P/E ratio of -1.03 indicates unprofitability over the last year.
• Karyopharm is advancing its clinical development pipeline with completed enrollment for a Phase 3 endometrial cancer trial and upcoming presentations at ASCO for its Phase 3 SENTRY trial.

Karyopharm Therapeutics (NASDAQ: KPTI) is a leading pharmaceutical company dedicated to developing innovative cancer treatments. The company recently unveiled its financial results for the first quarter of 2026, highlighting its progress. Its flagship commercial product, XPOVIO®, is a crucial therapy utilized in treating specific types of cancer.

On May 14, 2026, Karyopharm announced an earnings per share (EPS) of -$1.02. This impressive result significantly surpassed the consensus analyst estimate of -$1.45. As a key measure of a company's profitability, this EPS figure demonstrates substantial improvement from the $2.77 per share loss reported in the prior-year period.

The pharmaceutical company also reported robust revenue of $35.07 million, comfortably exceeding the estimated $31.40 million. This represents a notable increase from the $30 million in revenue generated in the same period last year. Specifically, U.S. net product revenue for XPOVIO® alone contributed $29.20 million. Karyopharm reaffirms its strong full-year 2026 revenue guidance of $130 million to $150 million, signaling continued growth in the oncology market.

Despite these positive financial indicators, Karyopharm currently holds a negative price-to-earnings (P/E) ratio of -1.03. This indicates that the company was not profitable over the past year, reflecting a net loss. The P/E ratio is a critical metric for investor valuation, comparing a company's share price to its earnings. A negative P/E specifically signifies negative earnings.

Operationally, Karyopharm is making significant strides in its clinical development pipeline. The company has successfully completed enrollment for its Phase 3 trial in endometrial cancer, with topline data anticipated in mid-2026, as reported by PR Newswire. Additionally, crucial results from Karyopharm's Phase 3 SENTRY trial are slated for presentation at the prestigious American Society of Clinical Oncology (ASCO) conference on June 2, further showcasing its commitment to oncology research.